Researchers from the University of Pennsylvania presented preliminary data from a trial evaluating Regeneron Pharmaceutical‘s (NSDQ:REGN) injectable biologic drug therapy for reducing triglyceride levels. The team, led by Dr. Richard Dunbar, presented their work at the annual meeting of the American Heart Assn.
The Phase I, placebo-controlled, double-blind study tested the safety and efficacy of Evinacumab, an investigational monoclonal antibody specifically engineered to inhibit a protein which enables high triglycerides. The study enrolled 41 participants and monitored them for at least 5 months following the injection.
Get the full story at our sister site, Drug Delivery Business News
The post Injectable Regeneron biologic therapy reduces triglycerides, cholesterol appeared first on MassDevice.
from MassDevice http://ift.tt/2gdicYx
Cap comentari:
Publica un comentari a l'entrada